Octreotide Therapy for Tumor-Induced Osteomalacia

Abstract

This Brief Report describes a patient with the rare syndrome of tumor-induced osteomalacia, which is accompanied by phosphaturia and hypophosphatemia. Renal phosphate wasting, presumably caused by phosphatonins, was abolished by octreotide, a synthetic somatostatin analogue, before successful surgical removal of a benign hemangiopericytoma.